4
Changes in Ownership
Protalix BioTherapeutics, Inc. Filed Acc 0001144204-12-026355
Executive VP, R&D sold 300,000 shares at $7.13 ($2,139,000)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Shaaltiel Yoseph Executive VP, R&D | 2012-05-02 | Sale | −300,000 | $7.13 | $2,139,000 | 463,754 | D |
| Open-market sales · 300,000 sh · avg $7.13 · $2,139,000 | |||||||
Loading xslF345X03/v311888_4.xml…